Inflectra market report projects growth on autoimmune demand and biosimilar adoption

The Business Research Company says the global Inflectra market is positioned for growth through 2026 as autoimmune disease prevalence rises and biosimilar use expands. Europe leads the market now, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - The Inflectra market is tied to treatment access for autoimmune diseases, where demand is rising for lower-cost biologic options. - Biosimilar adoption can help reduce pressure on healthcare budgets and widen patient access to TNF inhibitor therapies.

What happened: - The Business Research Company released its Detailed Inflectra Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market is being shaped by increasing autoimmune disease cases, clinical research activity and demand for affordable treatments. - The report includes a free sample download at Download a free sample of the inflectra market report. - The company also provides the full report at View the full inflectra market report.

The details: - Inflectra is the biosimilar name for infliximab-dyyb and is a biosimilar to Remicade, which contains infliximab. - Inflectra belongs to the TNF inhibitor class and targets TNF-alpha, a pro-inflammatory protein involved in immune responses. - The drug is used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis. - Historic market growth was supported by the high cost of originator TNF inhibitors, regulatory approvals that favored biosimilars, rising autoimmune disease burden, hospital formulary adoption and payer efforts to control costs. - The report expects future growth from biosimilar-friendly regulations, broader patient access to biologics, rising inflammatory disease prevalence, competitive pricing and greater physician familiarity with biosimilars. - Key forecast trends include more biosimilar adoption, cost-driven switching away from originator biologics, broader autoimmune treatment options, stronger physician confidence in biosimilar safety and more hospital-led biosimilar procurement. - The report says Europe held the largest Inflectra market share in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - Rising autoimmune disease prevalence is the core demand engine for Inflectra, since more patients can translate into more biosimilar use across hospital and payer channels. - Clinical trial volume can reinforce market confidence in biosimilars by expanding the evidence base around safety and effectiveness. - The report cites Canada’s inflammatory bowel disease burden as one example: more than 320,000 Canadians had IBD in September 2023, with prevalence at 825 per 100,000 people and an annual increase of 2.44%. - The same source projects Canada’s IBD population could reach 470,000 by 2035. - The report cites the US National Library of Medicine as saying ClinicalTrials.gov listed 404,637 interventional clinical trials as of March 2025, including 27,751 new trials started in 2023.

What's next: - The report expects continued market expansion through 2026 as biosimilar uptake widens and autoimmune disease treatment demand grows. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated visuals. - The company lists spokesperson and contact details for follow-up inquiries, including Saumya Sahay and marketing@tbrc.info.

The bottom line: - Inflectra’s growth story is being driven by a familiar mix of higher autoimmune disease prevalence, biosimilar-friendly policy and cost pressure on originator biologics.